![Bayer's drug that turns a cancer-protective pathway toxic eradicates breast tumors in mice | Fierce Biotech Bayer's drug that turns a cancer-protective pathway toxic eradicates breast tumors in mice | Fierce Biotech](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1626856483/bayer-office-building-socialmedia-1200x630.jpg/bayer-office-building-socialmedia-1200x630.jpg?VersionId=NGzveud.1RCGIotCel_XiAXW8GJRa9pm)
Bayer's drug that turns a cancer-protective pathway toxic eradicates breast tumors in mice | Fierce Biotech
Chris Brown, PHD, MBA Vice President, Academic Partnerships Systems Oncology LLC 7201 E. Henkel Way, Suite 205 Scottsdale, AZ, 8
![Cancer Center at Illinois on X: "CCIL scientists developed a promising breast cancer treatment leading to a licensing agreement with @Bayer and @SystemsOncology. The compound, ERSO, has been shown to target & Cancer Center at Illinois on X: "CCIL scientists developed a promising breast cancer treatment leading to a licensing agreement with @Bayer and @SystemsOncology. The compound, ERSO, has been shown to target &](https://pbs.twimg.com/media/EjP4x0mUcAAco8Y.jpg:large)
Cancer Center at Illinois on X: "CCIL scientists developed a promising breast cancer treatment leading to a licensing agreement with @Bayer and @SystemsOncology. The compound, ERSO, has been shown to target &
![Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire](https://mms.businesswire.com/media/20200915005685/en/821174/4/Systems_Oncology_logo.jpg)
Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire
![Bayer y Systems Oncology firman un acuerdo de licencia exclusivo sobre un abordaje innovador para el tratamiento del cáncer de mama ERSO Bayer y Systems Oncology firman un acuerdo de licencia exclusivo sobre un abordaje innovador para el tratamiento del cáncer de mama ERSO](http://www.pmfarma.com/noticias/noticias/29428/image/bayer.jpg)
Bayer y Systems Oncology firman un acuerdo de licencia exclusivo sobre un abordaje innovador para el tratamiento del cáncer de mama ERSO
![Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire](https://mms.businesswire.com/media/20200915005685/en/821173/4/Bayer_Logo.jpg)
Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire
![A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice | Science Translational Medicine A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice | Science Translational Medicine](https://www.science.org/cms/10.1126/scitranslmed.abf1383/asset/707b66b3-025d-4552-9766-edb2b08f809d/assets/graphic/abf1383-f4.jpeg)
A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice | Science Translational Medicine
![Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire](https://mms.businesswire.com/media/20200915005685/en/821173/3/Bayer_Logo.jpg)
Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™ | Business Wire
![Cancer compound originating from U of I scientists leads to major licensing deal | School of Molecular & Cellular Biology | UIUC Cancer compound originating from U of I scientists leads to major licensing deal | School of Molecular & Cellular Biology | UIUC](https://mcb.illinois.edu/sites/default/files/2022-05/erso%20molecule%20image.png)